Uniform sarcolemmal dystrophin expression is required to prevent extracellular microRNA release and improve dystrophic pathology

Uniform sarcolemmal dystrophin expression is required to prevent extracellular microRNA release and improve dystrophic pathology

<p><strong>Background:</strong> Duchenne muscular dystrophy (DMD) is a fatal muscle‐wasting disorder caused by genetic loss of dystrophin protein. Extracellular microRNAs (ex‐miRNAs) are putative, minimally invasive biomarkers of DMD. Specific ex‐miRNAs (e.g. miR‐1, miR‐13...

Full description

Bibliographic Details
Main Authors:	Van Westering, T, Lomonosova, Y, Coenen‐Stass, A, Betts, C, Bhomra, A, Hulsker, M, Clark, L, McClorey, G, Aartsma‐Rus, A, Putten, M, Wood, M, Roberts, T
Format:	Journal article
Language:	English
Published:	Wiley 2019

Similar Items

Uniform sarcolemmal dystrophin expression is required to prevent extracellular microRNA release and improve dystrophic pathology
by: Tirsa L.E. vanWestering, et al.
Published: (2020-04-01)

Profile of circadianly regulated metabolic genes in dystrophic heart
by: Betts, C, et al.
Published: (2018)

Exon skipping induces uniform dystrophin rescue with dose-dependent restoration of serum miRNA biomarkers and muscle biophysical properties
by: Chwalenia, K, et al.
Published: (2022)

Investigation of extracellular microRNAs and Serum Protein Biomarkers in dystrophic Muscle Disease
by: Coenen-Stass, A
Published: (2016)

Dystrophin involvement in peripheral circadian SRF signalling
by: Betts, CA, et al.
Published: (2021)

To dystrophin and beyond: an interview with Louis Kunkel
by: Louis M. Kunkel, et al.
Published: (2020-02-01)

Non-uniform dystrophin re-expression after CRISPR-mediated exon excision in the dystrophin/utrophin double-knockout mouse model of DMD
by: Hanson, B, et al.
Published: (2022)

Non-uniform dystrophin re-expression after CRISPR-mediated exon excision in the dystrophin/utrophin double-knockout mouse model of DMD
by: Britt Hanson, et al.
Published: (2022-12-01)

Sarcolemmal nNOS anchoring reveals a qualitative difference between dystrophin and utrophin.
by: Li, D, et al.
Published: (2010)

Sarcolemmal nNOS anchoring reveals a qualitative difference between dystrophin and utrophin
by: Li, D, et al.
Published: (2010)

Good news for the mdx mouse community: Improved dystrophin restoration after skipping mouse dystrophin exon 23
by: Annemieke Aartsma-Rus
Published: (2022-12-01)

Absence of the dystrophin protein in Duchenne muscular dystrophy: effects on transcriptome, proteome and microRNA secretome
by: van Westering, T
Published: (2018)

Cmah-dystrophin deficient mdx mice display an accelerated cardiac phenotype that is improved following peptide-PMO exon skipping treatment
by: Betts, C, et al.
Published: (2018)

The effects of low levels of dystrophin on mouse muscle function and pathology.
by: Maaike van Putten, et al.
Published: (2012-01-01)

Dystrophin R16/17-syntrophin PDZ fusion protein restores sarcolemmal nNOSμ
by: Aman Patel, et al.
Published: (2018-11-01)

A dystrophic Duchenne mouse model for testing human antisense oligonucleotides.
by: Marcel Veltrop, et al.
Published: (2018-01-01)

Dystrophin R16/17 protein therapy restores sarcolemmal nNOS in trans and improves muscle perfusion and function
by: Junling Zhao, et al.
Published: (2019-07-01)

Multiomic characterization of disease progression in mice lacking dystrophin.
by: Mirko Signorelli, et al.
Published: (2023-01-01)

Prevention of the dystrophic phenotype in dystrophin/utrophin-deficient muscle following adenovirus-mediated transfer of a utrophin minigene.
by: Wakefield, P, et al.
Published: (2000)

Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse.
by: Lu, Q, et al.
Published: (2003)

Metabolic remodeling of dystrophic skeletal muscle reveals biological roles for dystrophin and utrophin in adaptation and plasticity
by: Justin P. Hardee, et al.
Published: (2021-03-01)

Expression analysis in multiple muscle groups and serum reveals complexity in the microRNA transcriptome of the mdx mouse with implications for therapy.
by: Roberts, T, et al.
Published: (2012)

Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs.
by: Yokota, T, et al.
Published: (2012)

Influence of full-length dystrophin on brain volumes in mouse models of Duchenne muscular dystrophy.
by: Bauke Kogelman, et al.
Published: (2018-01-01)

Use of antisense-mediated exon skipping to generate dystrophin in muscles of the mdx dystrophic mouse
by: Lu, Q, et al.
Published: (2004)

Electroporation Enhanced Effect of Dystrophin Splice Switching PNA Oligomers in Normal and Dystrophic Muscle
by: Camilla Brolin, et al.
Published: (2015-01-01)

Glycine administration attenuates progression of dystrophic pathology in prednisolone-treated dystrophin/utrophin null mice
by: Daniel J. Ham, et al.
Published: (2019-09-01)

Low human dystrophin levels prevent cardiac electrophysiological and structural remodelling in a Duchenne mouse model
by: Gerard A. Marchal, et al.
Published: (2021-05-01)

Selective release of muscle-specific, extracellular microRNAs during myogenic differentiation.
by: Coenen-Stass, A, et al.
Published: (2016)

Allele-specific RNA interference to target a model of slow-channel congenital myasthenic syndrome
by: McClorey, G, et al.
Published: (2008)

Splice-switching therapy for spinal muscular atrophy.
by: Meijboom, K, et al.
Published: (2017)

Immortalized canine dystrophic myoblast cell lines for development of peptide-conjugated splice-switching oligonucleotides
by: Tone, Y, et al.
Published: (2021)

Sensitive and reliable evaluation of single-cut sgRNAs to restore dystrophin by a GFP-reporter assay.
by: Pin Lyu, et al.
Published: (2020-01-01)

Cell-penetrating peptide conjugates of steric blocking oligonucleotides as therapeutics for neuromuscular diseases from a historical perspective to current prospects of treatment
by: Gait, M, et al.
Published: (2018)

Prevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer-mediated exon-skipping.
by: Goyenvalle, A, et al.
Published: (2010)

A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice.
by: Yin, H, et al.
Published: (2009)

Advancing the potential of peptide-PMO compounds in exon skipping therapy for DMD
by: Godfrey, C, et al.
Published: (2012)

Assessment of RT-qPCR normalization strategies for accurate quantification of extracellular microRNAs in murine serum.
by: Thomas C Roberts, et al.
Published: (2014-01-01)

Modulating the expression of disease genes with RNA-based therapy.
by: Matthew Wood, et al.
Published: (2007-06-01)

Cell-penetrating peptides to enhance delivery of Oligonucleotide-based therapeutics
by: McClorey, G, et al.
Published: (2018)